Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Inflammation: Introduction01:12

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune checkpoint inhibitors.

The Journal of experimental medicine·2021
Same author

Cross-reactivity between cancer and microbial antigens.

Oncoimmunology·2021
Same author

Lower Airway Dysbiosis Exacerbates Lung Cancer.

Cancer discovery·2021
Same author

Subversion of calreticulin exposure as a strategy of immune escape.

Cancer cell·2021
Same author

Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota.

Frontiers in immunology·2020
Same author

Immunodynamics of explanted human tumors for immuno-oncology.

EMBO molecular medicine·2020

Related Experiment Video

Updated: May 15, 2026

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
07:44

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

Neutralizing tumor-promoting chronic inflammation: a magic bullet?

Lisa M Coussens1, Laurence Zitvogel, A Karolina Palucka

  • 1Department of Cell and Developmental Biology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239-3098, USA. coussenl@ohsu.edu

Science (New York, N.Y.)
|January 19, 2013
PubMed
Summary

Recent cancer therapies target genetic aberrations and tumor vascularization. New immunotherapeutics leverage the understanding that certain immune cells promote tumor growth, offering novel strategies to combat cancer-associated inflammation.

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
07:49

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

Related Experiment Videos

Last Updated: May 15, 2026

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
07:44

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports

Published on: November 28, 2019

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
07:49

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Cancer diagnostics and therapies have advanced significantly over the last decade.
  • Current treatments include chemotherapy, radiation, targeting cancer cell-intrinsic mediators, and modulating cancer cell-extrinsic pathways.
  • Immunotherapeutics have emerged, recognizing the role of chronically activated immune cells in fostering tumor development.

Purpose of the Study:

  • To review clinical and experimental studies on the protumorigenic roles of immune cells in cancer-associated inflammation.
  • To discuss the potential of targeting these immune cells to reprogram their function.
  • To explore how reprogramming immune cells can neutralize chronic inflammation and facilitate cancer rejection.

Main Methods:

  • Review of clinical studies.
  • Analysis of experimental studies.
  • Delineation of protumorigenic roles of immune cell subsets.
  • Discussion of targeting strategies for immune cell reprogramming.

Main Results:

  • Identified specific immune cell subsets that play protumorigenic roles in cancer-associated inflammation.
  • Highlighted that these immune cells can be targeted to alter their function.
  • Demonstrated that reprogramming these cells can resolve or neutralize cancer-promoting inflammation.

Conclusions:

  • Targeting immune cell subsets involved in chronic inflammation offers a promising therapeutic strategy.
  • Reprogramming these cells can lead to the resolution of cancer-promoting inflammation.
  • This approach facilitates cancer rejection and improves therapeutic outcomes.